Allergic Rhinitis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Allergic Rhinitis – Pipeline Review, H2 2019’, provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis

– The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects

– The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Advagene Biopharma Co Ltd

ALK-Abello AS

Allovate LLC

AOBiome LLC

ASIT Biotech SA

Chrysalis BioTherapeutics Inc

CSPC Pharmaceutical Group Ltd

Dobecure SL

Emergo Therapeutics Inc

Fountain Biopharma Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

HAL Allergy BV

Inimmune Corp

Inmunotek SL

JiangSu Qyuns Therapeutics Co Ltd

Kolmar Korea Holdings Co Ltd

Laboratorios LETI SL

Link Health Group

Marinomed Biotech AG

Mitsubishi Tanabe Pharma Corp

Navipharm Co Ltd

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Regeneron Pharmaceuticals Inc

Roxall Medizin GmbH

Sam-A Pharm Co Ltd

Sedor Pharmaceuticals LLC

Shouyao Holding Co Ltd

Stallergenes Greer plc

The Geneva Biotech Center SA

Vactech Oy

Wolwo Pharma

Wuhan Yicheng Biotechnology Co Ltd

Xencor Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Allergic Rhinitis Overview 6

Allergic Rhinitis Therapeutics Development 7

Allergic Rhinitis Therapeutics Assessment 15

Allergic Rhinitis Companies Involved in Therapeutics Development 23

Allergic Rhinitis Drug Profiles 36

Allergic Rhinitis Dormant Projects 116

Allergic Rhinitis Discontinued Products 123

Allergic Rhinitis Product Development Milestones 125

Appendix 135

List of Tables

“List of Tables

Number of Products under Development for Allergic Rhinitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Allergic Rhinitis – Pipeline by Advagene Biopharma Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by ALK-Abello AS, H2 2019

Allergic Rhinitis – Pipeline by Allovate LLC, H2 2019

Allergic Rhinitis – Pipeline by AOBiome LLC, H2 2019

Allergic Rhinitis – Pipeline by ASIT Biotech SA, H2 2019

Allergic Rhinitis – Pipeline by Chrysalis BioTherapeutics Inc, H2 2019

Allergic Rhinitis – Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019

Allergic Rhinitis – Pipeline by Dobecure SL, H2 2019

Allergic Rhinitis – Pipeline by Emergo Therapeutics Inc, H2 2019

Allergic Rhinitis – Pipeline by Fountain Biopharma Inc, H2 2019

Allergic Rhinitis – Pipeline by GlaxoSmithKline Plc, H2 2019

Allergic Rhinitis – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019

Allergic Rhinitis – Pipeline by HAL Allergy BV, H2 2019

Allergic Rhinitis – Pipeline by Inimmune Corp, H2 2019

Allergic Rhinitis – Pipeline by Inmunotek SL, H2 2019

Allergic Rhinitis – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by Kolmar Korea Holdings Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by Laboratorios LETI SL, H2 2019

Allergic Rhinitis – Pipeline by Link Health Group, H2 2019

Allergic Rhinitis – Pipeline by Marinomed Biotech AG, H2 2019

Allergic Rhinitis – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019

Allergic Rhinitis – Pipeline by Navipharm Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019

Allergic Rhinitis – Pipeline by Pfizer Inc, H2 2019

Allergic Rhinitis – Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Allergic Rhinitis – Pipeline by Roxall Medizin GmbH, H2 2019

Allergic Rhinitis – Pipeline by Sam-A Pharm Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by Sedor Pharmaceuticals LLC, H2 2019

Allergic Rhinitis – Pipeline by Shouyao Holding Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by Stallergenes Greer plc, H2 2019

Allergic Rhinitis – Pipeline by The Geneva Biotech Center SA, H2 2019

Allergic Rhinitis – Pipeline by Vactech Oy, H2 2019

Allergic Rhinitis – Pipeline by Wolwo Pharma, H2 2019

Allergic Rhinitis – Pipeline by Wuhan Yicheng Biotechnology Co Ltd, H2 2019

Allergic Rhinitis – Pipeline by Xencor Inc, H2 2019

Allergic Rhinitis – Dormant Projects, H2 2019

Allergic Rhinitis – Discontinued Products, H2 2019

Allergic Rhinitis – Discontinued Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Allergic Rhinitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports